LY 329960

Drug Profile

LY 329960

Latest Information Update: 03 Feb 2000

Price : $50

At a glance

  • Originator Eli Lilly
  • Class Anti-infectives
  • Mechanism of Action Glucan synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Mycoses

Most Recent Events

  • 03 Feb 2000 No-Development-Reported for Mycoses in USA (IV)
  • 01 May 1997 New profile
  • 01 May 1997 Preclinical development for Mycoses in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top